Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2006-02-08
2009-12-08
Mosher, Mary E (Department: 1648)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
Reexamination Certificate
active
07629443
ABSTRACT:
The present invention provides an isolated antibody capable of binding to the receptor-binding domain of the spike protein of the severe acute respiratory syndrome-associated coronavirus (SARS-CoV) so as to competitively inhibit the binding of the SARS-CoV to host cells. These mAbs or substances can be used: 1) as passive-immunizing agents for prevention of SARS-CoV infection; 2) as biological reagents for diagnosis of SARS-CoV infection; 3) as immunotherapeutics for early treatment of SARS-CoV infection; and 4) as probes for studying the immunogenicity, antigenicity, structure, and function of the SARS-CoV S protein.
REFERENCES:
patent: 2005/0249739 (2005-11-01), Marasco et al.
Sui et al (PNAS 101:2536-2541, 2004).
May 3, 2007 PCT Invitation to Pay Additional Fees and, Where Applicable, Protest Fees, for New York Blood Center, International Application No. PCT/US06/04599, filed Feb. 8, 2006.
Jun. 4, 2007 Response to PCT Invitation to Pay Additional Fees and, Where Applicable, Protest Fees, for New York Blood Center, International Application No. PCT/US06/04599, filed Feb. 8, 2006.
Jan. 31, 2008 PCT International Search Report and Written Opinion, for New York Blood Center, International Application No. PCT/US06/04599, filed Feb. 8, 2006.
Choy et al. “Synthetic peptide studies on the severe acute respiratory syndrome (SARS) coronavirus spike glycoprotein: perspective for SARS vaccine development.” Clinical Chemistry 2004, 50(6), 1036-1042.
Drosten, C. et al., 2003, “Identification of a Novel Coronavirus in Patients with Severe Acute Respiratory Syndrome”, N. Engl. J. Med. 348:1967-1976.
Ksiazek, T.G. et al., 2003, “A Novel Coronavirus Associated with Severe Acute Respiratory Syndrome”, N. Engl. J. Med. 348:1953-1966.
Peiris, J.S. et al., 2003, “Coronavirus as a possible cause of severe acute respiratory syndrome”, Lancet 361:1319-1325.
Marra, M.A. et al., 2003, “The Genome Sequence of the SARS-Associated Coronavirus”, Science 300:1399-1404.
Rota, P.A. et al., 2003, “Characterization of a Novel Coronavirus Associated with Severe Acute Respiratory Syndrome”, Science 300:1394-1399.
Du, L. et al., 2007, “Cleavage of spike protein of SARS coronavirus by protease factor Xa is associated with viral infectivity”, Biochem. Biophys. Res. Commun. 359:174-179.
Marshall, E. et al., 2004, “Caution Urged on SARS vaccines”, Science 303:944-946.
Peiris, J.S. et al., 2004, “Severe acute respiratory syndrome”, Nat. Med. 10:S88-S97.
Du, L. et al., 2007, “Receptor-binding domain of SARS-CoV spike protein induces long-term protective immunity in an animal model”, Vaccine 25:2832-2838.
Holmes, K.V. et al., 2003, “Virology: The SARS Coronavirus: A postgenomic Era”, Science 300:1377-1378.
Holmes, K.V., 2003, “SARS coronavirus: a new challenge for prevention and therapy”, J. Clin. Invest. 111:1605-1609.
He, Y. et al., 2006, “Cross-Neutralization of Human and Palm Civet Severe Acute Respiratory Syndrome Coronavirus by Targeting the Receptor-Binding Domain of Spike Protein”, J. Immunol. 176, 6085-6092.
He, Y. et al., 2006, “Antigenic and Immunogenic Characterization of Recombinant Baculovirus-Expressed Severe Acute Respiratory Syndrome Coronavirus Spike Protein: Implication for Vaccine Design”, J. Virol. 80:5757-5767.
Chen, Z. et al., 2005, “Recombinant Modified Vaccinia Virus Ankara Expressing the Spike Glycoprotein of Severe Acute Respiratory Syndrome Coronavirus Induces Protective Neutralizing Antibodies Primarily Targeting the Receptor Binding Region”, J. Virol. 79:2678-2688.
Bosch, B.J. et al., 2004, “Severe acute respiratory syndrome coronavirus (SARS-CoV) infection inhibition using spike protein heptad repeat-derived peptides”, Proc. Natl. Acad. Sci. USA 101:8455-8460.
Ingallinella, P., E. et al., 2004, “Structural characterization of the fusion-active complex of severe acute respiratory syndrome (SARS) coronavirus”, Proc. Natl. Acad. Sci. USA 101:8709-8714.
Liu, S. et al., 2004, “Interaction between the heptad repeat 1 and 2 regions in spike protein of SARS-associated coronavirus: implication for virus fusogenic mechanism and identification of fusion inhibitors”, Lancet 363:938-947.
Yi, C. E. et al., 2005, “Single Amino Acid Substitutions in the Severe Acute Respiratory Syndrome Coronavirus Spike Glycoprotein Determine Viral Entry and lmmunogenicity of a Major Neutralizing Domain”, J. Virol. 79:11638-11646.
Du, L. et al., 2006, “Recombinant adeno-associated virus expressing the receptor-binding domain of severe acute respiratory syndrome coronavirus S protein elicits neutralizing antibodies: Implication for developing SARS vaccines”, Virology 353:6-16.
Bosch, B.J. et al., 2003, “The Coronavirus Spike Protein Is a Class I Virus Fusion Protein: Structural and Functional Characterization of the Fusion Core Complex”, J. Virol. 77:8801-8811.
Xu, Y. et al., 2004, “Crystal Structure of Severe Acute Respiratory Syndrome Coronavirus Spike Protein Fusion Core”, J. Biol. Chem. 279:49414-49419.
Li, W. et al., 2003, “Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus”, Nature 426:450-454.
Dimitrov, D.S., 2003, “The Secret Life of ACE2 as a receptor for the SARS Virus”, Cell 115:652-653.
Prabakaran, P. et al., 2004, “A model of the ACE2 structure and function as a SARS-CoV receptor”, Biochem. Biophys. Res. Commun. 314:235-241.
Wang, P. et al., 2004, “Expression cloning of functional receptor used by SARS coronavirus”, Biochem. Biophys. Res. Commun. 315:439-444.
Xiao, X., S. Chakraborti et al., 2003, “The SARS-CoV S glycoprotein: expression and functional characterization”, Biochem. Biophys. Res. Commun. 312:1159-1164.
Wong, S.K. et al., 2004, “A 193-Amino-Acid Fragment of the SARS Coronavirus S Protein Efficiently Binds Angiotensin-converting Enzyme 2”, J. Biol. Chem. 279:3197-3201.
Babcock, G.J. et al., 2004, “Amino Acids 270 to 510 of the Severe Acute Respiratory Syndrome Coronavirus Spike Protein Are Required for Interaction with Receptor”, J. Virol. 78:4552-4560.
He, L. et al., 2006, “Expression of elevated levels of pro-inflammatory cytokines in SARS-CoV-infected ACE2+ cells in SARS patients: relation to the acute lung injury and pathogenesis of SARS”, J. Pathol. 210:288-297.
Liu, L. et al., 2007, “Natural Mutations in the Receptor Binding Domain of Spike Glycoprotein Determine the Reactivity of Cross-Neutralization between Palm Civet Coronavirus and Severe Acute Respiratory Syndrome Coronavirus”, J Virol. 81:4694-700.
Buchholz, U.J. et al., 2004, “Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity”, Proc. Natl. Acad. Sci. USA 101:9804-9809.
Yang, Z.Y. et al., 2004, “A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice”, Nature 428:561-564.
Bisht, H. et al., 2004, “Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice”, Proc. Natl. Acad. Sci. USA 101:6641-6646.
Bukreyev, A. et al., 2004, “Mucosal immunisation of African green monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS”, Lancet 363:2122-2127.
He, Y. et al., “Receptor-binding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies: implication for developing subunit vaccine”, Biochem. Biophys. Res. Commun. 324:773-781, (2004).
He, Y. et al., 2004, “Inactivated SARS-CoV vaccine elicits high titers of spike protein-specific antibodies that block receptor binding and virus entry”, Biochem. Biophys. Res. Commun. 325:445-452.
Morrison,
He Yuxian
Jiang Shibo
Cullman Louis C.
K&L Gates LLP
Mosher Mary E
New York Blood Center Inc.
LandOfFree
Neutralizing monoclonal antibodies against severe acute... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Neutralizing monoclonal antibodies against severe acute..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Neutralizing monoclonal antibodies against severe acute... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4057085